AVH AVITA Medical CDI

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit .

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.



Investor & Media Contact:
Jessica Ekeberg
Phone  
 
 
EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AVITA Medical CDI

 PRESS RELEASE

Data Presented at the 2025 Southern Region Burn Conference Reinforce R...

Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the cli...

 PRESS RELEASE

AVITA Medical to Announce Third Quarter 2025 Financial Results

AVITA Medical to Announce Third Quarter 2025 Financial Results VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m. Australian Eastern Daylight Tim...

 PRESS RELEASE

AVITA Medical Welcomes Support for RECELL® in Burns in Australia

AVITA Medical Welcomes Support for RECELL® in Burns in Australia Australia’s Medical Services Advisory Committee (MSAC) recognizes RECELL® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia’s Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) to include the use of autologous skin cell suspen...

 PRESS RELEASE

AVITA Medical Announces CEO Transition

AVITA Medical Announces CEO Transition Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is lea...

 PRESS RELEASE

CMS New Technology Add-On Payment Expands Access to RECELL® for Patien...

CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today announced that beginning October 1, 2025, hospitals across the U.S. will be eligible f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch